STRC Gene Hearing Loss: Comprehensive Guide
Context: Research for Egor’s son, diagnosed with moderate bilateral sensorineural hearing loss caused by compound heterozygous STRC gene mutations.
Key Findings
- STRC-related hearing loss (DFNB16) is 2nd most common hereditary hearing loss
- Affects ~2.3M people worldwide
- Typically congenital, bilateral, mild-to-moderate (40-50 dB), generally STABLE over lifetime
- Hair cells remain ALIVE and structurally intact (just lack stereocilin protein)
- This creates broad window for future gene therapy (infancy through adulthood)
Treatment Horizon
- Dual-AAV gene replacement restored hearing in mice
- OTOF gene therapy restored hearing in dozens of deaf children (2022-2025 trials)
- Regeneron has preclinical STRC program (AAV.104) in pipeline
- Hearing aids: standard of care, highly effective for moderate loss
Files
- English:
~/DeepResearch/2026-02-07-strc-hearing-loss-treatment.md - Russian:
~/DeepResearch/2026-02-07-strc-hearing-loss-treatment-RU.md
Connections
-
[see-also]Sound Therapy and Hearing Loss -
[see-also]Misha Medical Timeline -
[see-also]Gut-Brain Axis and Neurodevelopment -
[see-also]Misha 6-Month Action Plan 2026 -
[see-also]DR - Misha French Social Protection -
[see-also]Misha Diagnostic Assessments -
[see-also]Misha Therapy Providers HK -
[see-also]France MDPH Disability Benefits -
[see-also]Misha Psychologist Session 2026-02-27 -
[see-also]Allergy-Inflammation-Behavior Pathway -
Egor Lyfar - personal/family context